Please assess the completion status of the following clinical trial:

Trial Title: Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Signed informed consent prior to participation.~2. Diagnosis of chronic obstructive pulmonary disease and post-bronchodilator FEV1(Forced Expiratory Volume in 1 sec) \<80% of predicted normal and post-bronchodilator FEV1(Forced Expiratory Volume in 1 sec)/FVC of \< 70% at Visit 1.~3. Male or female between 40 and 75 years of age.~4. Current or ex-smokers with smoking history of more than 10-pack years.~5. Able to perform technically acceptable pulmonary function tests, multiple exercise tests and able to maintain records.~6. Able to inhale medication in a competent manner from a metered-dose inhaler and Respimat inhaler.~Exclusion criteria:~1. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT \>x2 ULN, SGPT \>x2 ULN, bilirubin \>x2 ULN or creatinine \>x2 ULN.~2. Patients with a history of asthma and/or total blood eosinophil count of 600 cells/mm3.~3. Patients with thyrotoxicosis, paroxysmal tachycardia (\>100 beats per minute).~4. Patients with a history of myocardial infarction within 1 year of screening visit, unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure within the past year, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, significant alcohol or drug abuse or contraindications to exercise.~5. Patients who have undergone thoracotomy with pulmonary resection.~6. Patients being treated with oral beta-adrenergics or oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.~7. Patients who regularly use daytime oxygen for more than one hour per day.~8. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.~9. Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnea.~10. Pregnant or nursing women.~11. Women of childbearing potential not using two effective methods of birth control (one barrier and one non-barrier).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI 1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from the Respimat inhaler
- Olodaterol (BI 1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from the Respimat inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).